glp-1 receptor agonists for weight loss Frontiers | Exploring the multifaceted

Yes, there is a new, non-injectable version of oral semaglutide by Wegovy that came on the market in January 2026

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, has emerged as a significant complication of pediatric obesity

Charlotte, NC: American College of Gastroenterology

However, not everyone is a candidate for these medications, and others might prefer to explore alternatives

[DOI] [PubMed] [Google Scholar] 3.Peeters A., Barendregt J.J., Willekens F., Mackenbach J.P., Mamun A.A., Bonneux L

In the safety profile, pooling three studies with 640 patients, most adverse events associated with retatrutide were mild and did not result in treatment discontinuation